IL255448B2 - Inhibitors of histone deacetylase and their compositions and methods of use - Google Patents

Inhibitors of histone deacetylase and their compositions and methods of use

Info

Publication number
IL255448B2
IL255448B2 IL255448A IL25544817A IL255448B2 IL 255448 B2 IL255448 B2 IL 255448B2 IL 255448 A IL255448 A IL 255448A IL 25544817 A IL25544817 A IL 25544817A IL 255448 B2 IL255448 B2 IL 255448B2
Authority
IL
Israel
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
mixture
membered
Prior art date
Application number
IL255448A
Other languages
English (en)
Hebrew (he)
Other versions
IL255448A0 (en
IL255448B1 (en
Inventor
Dominguez Celia
C Maillard Michel
F Haughan Alan
VAN DE POEL Amanda
J Stott Andrew
A Luckhurst Christopher
A Saville-Stones Elizabeth
Wishart Grant
Wall Michael
Breccia Perla
E Jarvis Rebecca
Original Assignee
Chdi Foundation Inc
Dominguez Celia
C Maillard Michel
F Haughan Alan
VAN DE POEL Amanda
J Stott Andrew
A Luckhurst Christopher
Elizabeth A Saville Stones
Wishart Grant
Wall Michael
Breccia Perla
E Jarvis Rebecca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chdi Foundation Inc, Dominguez Celia, C Maillard Michel, F Haughan Alan, VAN DE POEL Amanda, J Stott Andrew, A Luckhurst Christopher, Elizabeth A Saville Stones, Wishart Grant, Wall Michael, Breccia Perla, E Jarvis Rebecca filed Critical Chdi Foundation Inc
Publication of IL255448A0 publication Critical patent/IL255448A0/en
Publication of IL255448B1 publication Critical patent/IL255448B1/en
Publication of IL255448B2 publication Critical patent/IL255448B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
IL255448A 2015-05-07 2017-11-06 Inhibitors of histone deacetylase and their compositions and methods of use IL255448B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562158363P 2015-05-07 2015-05-07
PCT/US2016/031335 WO2016179554A1 (en) 2015-05-07 2016-05-06 Histone deacetylase inhibitors and compositions and methods of use thereof

Publications (3)

Publication Number Publication Date
IL255448A0 IL255448A0 (en) 2017-12-31
IL255448B1 IL255448B1 (en) 2023-03-01
IL255448B2 true IL255448B2 (en) 2023-07-01

Family

ID=57218014

Family Applications (1)

Application Number Title Priority Date Filing Date
IL255448A IL255448B2 (en) 2015-05-07 2017-11-06 Inhibitors of histone deacetylase and their compositions and methods of use

Country Status (11)

Country Link
US (2) US10053434B2 (OSRAM)
EP (1) EP3291810B1 (OSRAM)
JP (1) JP6805172B2 (OSRAM)
KR (1) KR20180002729A (OSRAM)
CN (1) CN107735088B (OSRAM)
AU (1) AU2016258188B2 (OSRAM)
CA (1) CA2984618C (OSRAM)
EA (1) EA036965B1 (OSRAM)
IL (1) IL255448B2 (OSRAM)
MX (1) MX378983B (OSRAM)
WO (1) WO2016179554A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180002730A (ko) 2015-05-07 2018-01-08 씨에이치디아이 파운데이션, 인코포레이티드 히스톤 탈아세틸효소 억제제 및 그것의 조성물 및 사용 방법
AU2016258188B2 (en) * 2015-05-07 2021-08-26 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
US10757941B2 (en) * 2016-07-22 2020-09-01 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
CN109627207A (zh) * 2018-12-17 2019-04-16 天津药明康德新药开发有限公司 一种3-(二氟甲氧基)哌啶盐酸盐的制备方法
WO2022174193A1 (en) * 2021-02-15 2022-08-18 The Research Foundation For The State University Of New York Radiolabeled compositions and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013008162A1 (en) * 2011-07-08 2013-01-17 Novartis Ag Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006061638A2 (en) 2004-12-10 2006-06-15 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Heterocycle derivatives as histone deacetylase (hdac) inhibitors
KR101781663B1 (ko) 2010-01-13 2017-09-25 템페로 파마슈티칼즈, 인크. 히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법
WO2013006408A1 (en) * 2011-07-01 2013-01-10 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2013009830A1 (en) * 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009810A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
MY166890A (en) 2011-08-30 2018-07-24 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2013066833A1 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods to inhibit histone deacetylase (hdac) enzymes
WO2013066835A2 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
BR112014012815A8 (pt) * 2011-11-28 2017-06-20 Novartis Ag derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
ES2972419T3 (es) * 2012-04-05 2024-06-12 Chdi Foundation Inc Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas y métodos de uso de los mismos
AU2016258188B2 (en) * 2015-05-07 2021-08-26 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
KR20180002730A (ko) 2015-05-07 2018-01-08 씨에이치디아이 파운데이션, 인코포레이티드 히스톤 탈아세틸효소 억제제 및 그것의 조성물 및 사용 방법
KR101799005B1 (ko) 2015-07-27 2017-11-17 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설프아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물
NZ739026A (en) 2015-07-27 2019-03-29 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
BR112018002304B1 (pt) 2015-08-04 2023-12-19 Chong Kun Dang Pharmaceutical Corp Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013008162A1 (en) * 2011-07-08 2013-01-17 Novartis Ag Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease

Also Published As

Publication number Publication date
MX378983B (es) 2025-03-10
EP3291810B1 (en) 2022-08-10
AU2016258188A1 (en) 2017-11-23
IL255448A0 (en) 2017-12-31
CA2984618C (en) 2024-01-09
CN107735088A (zh) 2018-02-23
JP6805172B2 (ja) 2020-12-23
EA036965B1 (ru) 2021-01-20
IL255448B1 (en) 2023-03-01
CN107735088B (zh) 2021-11-02
AU2016258188B2 (en) 2021-08-26
BR112017023711A2 (pt) 2018-07-17
HK1252487A1 (en) 2019-05-24
EA201792247A1 (ru) 2018-06-29
MX2017014300A (es) 2018-08-09
EP3291810A1 (en) 2018-03-14
EP3291810A4 (en) 2018-11-07
US10053434B2 (en) 2018-08-21
WO2016179554A1 (en) 2016-11-10
US20160326124A1 (en) 2016-11-10
JP2018515489A (ja) 2018-06-14
KR20180002729A (ko) 2018-01-08
US20190202795A1 (en) 2019-07-04
CA2984618A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
AU2016256917B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
IL255448B2 (en) Inhibitors of histone deacetylase and their compositions and methods of use
US9765054B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
US9783488B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
EP2871955A1 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
EP2968207A1 (en) Histone deacetylase inhibitors and compositions
HK1252487B (en) Histone deacetylase inhibitors and compositions and methods of use thereof
HK1252489B (en) Histone deacetylase inhibitors and compositions and methods of use thereof
BR112017023711B1 (pt) Inibidores de histona deacetilase e composições e métodos de uso dos mesmos